证券代码：603987 证券简称：康德莱 公告编号：2025-026 上海康德莱企业发展集团股份有限公司 第五届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海康德莱企业发展集团股份有限公司（以下简称"公司"）第五届董事会 第十九次会议（以下简称"会议"）于 2025 年 10 月 27 日在上海市嘉定区高潮路 658 号会议室以现场结合通讯表决方式召开，会议通知及相关会议文件于 2025 年 10 月 22 日以电子邮件方式向全体董事、监事及高级管理人员发出。会议应出 席董事 9 名，实际出席董事 9 名。会议由董事长张宪淼先生主持，公司监事、财 务总监及董事会秘书列席会议。本次会议符合《中华人民共和国公司法》《上海 证券交易所股票上市规则》等有关法律、行政法规、部门规章、规范性文件和《上 海康德莱企业发展集团股份有限公司章程》的规定。 二、董事会会议审议情况 （一）审议通过了《公司 2025 年第三季度报告》； 公司第五届董事会审计委员会在本次董事会召开前已就本议案发 ...

上海康德莱企业发展集团股份有限公司 2025 年第三季度报告 证券代码：603987 证券简称：康德莱 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 596,335,800.75 | 2.44 | 1,721,227,965.20 | 0.95 | | 利润总额 | 94,584,623.32 | 29.11 | 245,330,326.35 | 24.22 | | 归属于上市公司股东的 净利润 | 68,504,816.22 | 14.33 | 193,536,645.77 | 17.27 | | 归属于上市公司股东的 扣除非经常性损益的净 | 65,461,509.63 | 10.25 | 188,548,914.17 | 16.06 | | 利润 | | | | | | 经营活动产生的现金流 | ...

Core Insights - The company reported third-quarter revenue of 596 million, representing a year-on-year increase of 2.44% [1] - Net profit for the third quarter was 68.5 million, showing a year-on-year growth of 14.33% [1] - For the first three quarters, total revenue reached 1.721 billion, with a year-on-year increase of 0.95% [1] - Net profit for the first three quarters was 194 million, reflecting a year-on-year growth of 17.27% [1]

一、协议转让前期基本情况 证券代码：603987 证券简称：康德莱 公告编号：2025-025 上海康德莱企业发展集团股份有限公司 关于公司控股股东协议转让股份过户完成的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海康德莱企业发展集团股份有限公司（以下简称"公司"）控股股东上 海康德莱控股集团有限公司（以下简称"康德莱控股集团"）与长沙械字号医疗 投资有限公司（以下简称"长沙械字号"）于 2025 年 9 月 1 日签署了《股份转让 协议》。康德莱控股集团以 10.81 元/股的价格转让其持有的公司无限售流通股 21,839,544 股（占公司总股本的 5%）给长沙械字号。 本次协议转让完成后，长沙械字号持有公司 6.45%股份，其将承诺依照 《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所上市公司 自律监管指引第 15 号——股东及董事、高级管理人员减持股份》等相关法律法 规，严格履行上市公司股东义务；同时承诺自交割完成之日起，对所受让的股份 12 个月内不减持。 本次协 ...

Core Viewpoint - Kangdelai's controlling shareholder, Kangdelai Holdings Group, has transferred approximately 21.84 million unrestricted circulating shares (5% of total share capital) at a price of 10.81 yuan per share to Changsha Medical [1] Group 1: Share Transfer Details - The share transfer transaction has received compliance confirmation from the Shanghai Stock Exchange and the transfer registration procedures have been completed [1] - The transfer date was October 21, 2025, and the shares involved are unrestricted circulating shares [1] Group 2: Company Financials - For the year 2024, Kangdelai's revenue composition is as follows: 99.6% from medical device manufacturing and 0.4% from other businesses [1] - As of the report date, Kangdelai's market capitalization is 4 billion yuan [1]

Core Viewpoint - The company, Kangdelai, is actively monitoring market trends and responding proactively to investor inquiries as of October 16 [2] Company Summary - Kangdelai is engaged in ongoing market observation and is committed to addressing market dynamics [2]

Core Viewpoint - The company is actively expanding its non-US market and enhancing the promotion of specialized products to mitigate the impact of tariffs [1] Group 1 - The company has responded to investor inquiries regarding its operational status, indicating that business operations are normal [1] - Market expansion efforts are progressing in an orderly manner [1]

Core Viewpoint - The company, Kangdelai (603987), has confirmed that its international business accounts for approximately 36% of its operations, and it emphasizes strict risk control and safe management practices [1] Summary by Categories Company Operations - Kangdelai's international business is settled in foreign currencies, indicating a significant portion of its revenue is derived from global markets [1] - The company has reported that its international business constitutes about 36% of its total operations, highlighting its reliance on international markets [1] Risk Management - The company has stated that it maintains strict risk control measures to ensure safe operations, reflecting a proactive approach to managing potential financial risks associated with international business [1]

Core Viewpoint - Kangdelai's stock price has shown a significant increase of 30.58% year-to-date, indicating strong market performance despite recent fluctuations [2]. Group 1: Stock Performance - As of October 15, Kangdelai's stock price rose by 2.00% to 9.18 CNY per share, with a trading volume of 53.07 million CNY and a turnover rate of 1.34%, resulting in a total market capitalization of 4.01 billion CNY [1]. - Year-to-date, Kangdelai's stock has increased by 30.58%, with a 1.77% rise over the last five trading days, a 3.37% decline over the last 20 days, and a 15.04% increase over the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Kangdelai reported a revenue of 1.125 billion CNY, reflecting a year-on-year growth of 0.17%, while the net profit attributable to shareholders was 125 million CNY, marking an 18.94% increase [3]. - Since its A-share listing, Kangdelai has distributed a total of 530 million CNY in dividends, with 231 million CNY distributed over the past three years [4]. Group 3: Shareholder Information - As of June 30, 2025, Kangdelai had 26,300 shareholders, an increase of 1.72% from the previous period, with an average of 16,632 circulating shares per shareholder, a decrease of 1.69% [3]. - The top ten circulating shareholders include Guoshou Anbao Wisdom Life Stock A and招商量化精选股票发起式A, holding 4.21 million shares and 3.27 million shares respectively, with the latter seeing a reduction of 2.51 million shares compared to the previous period [4].

Core Points - Company has obtained the land use rights certificate for a specific plot in Shanghai, indicating a significant step in its real estate development strategy [1] - The land is designated for research and design purposes, with a total area of 15,080.10 square meters and a building area of 46,624.68 square meters [1] - The land use rights are granted for a period from December 21, 2021, to December 20, 2071, ensuring long-term operational capacity for the company [1] Summary by Sections - **Acquisition Details** - Company won the bidding for the land use rights through an online platform managed by the Shanghai Municipal Bureau of Planning and Natural Resources [1] - The land is located at 587 Gaochao Road, Jiading District, Shanghai [1] - **Land Use and Ownership** - The company holds the land use rights and property ownership solely [1] - The land is classified as state-owned construction land with a purpose for research and design [1] - **Legal and Regulatory Compliance** - The board of directors guarantees the accuracy and completeness of the announcement, affirming legal responsibility for the information provided [1][2]